Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above 200 Day Moving Average - Here's Why

Key Points

• Hikma Pharmaceuticals shares rose above their 200-day moving average, reaching GBX 1,541 and last trading at GBX 1,531, up 2.2% with more than 28 million shares changing hands.
• Analysts remain bullish: all six covering analysts rate the stock a Buy, with a consensus price target of GBX 2,085.83. Several firms recently raised their targets, including Berenberg to GBX 2,100 and Jefferies to GBX 2,025.
• Insider confidence was highlighted by Tobias Hestler’s purchase of 7,500 shares for £123,600; company insiders collectively own 22.26% of Hikma’s stock.

Shares of Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 1,461.88 and traded as high as GBX 1,541. Hikma Pharmaceuticals shares last traded at GBX 1,531, with a volume of 28,126,924 shares.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Berenberg Bank boosted their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Citigroup boosted their target price on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Finally, Jefferies Financial Group upped their target price on shares of Hikma Pharmaceuticals from GBX 1,870 to GBX 2,025 and gave the stock a "buy" rating in a research report on Tuesday, August 25th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of GBX 2,085.83.

Hikma Pharmaceuticals Trading Up 2.2%

The firm has a market cap of £3.17 billion, a P/E ratio of 8.70, a P/E/G ratio of 2.38 and a beta of 0.66. The stock has a 50 day simple moving average of GBX 1,599.21 and a 200-day simple moving average of GBX 1,461.88. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57.

Insiders Place Their Bets

In other Hikma Pharmaceuticals news, insider Tobias Hestler purchased 7,500 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average price of GBX 1,648 per share, for a total transaction of £123,600. Corporate insiders own 22.26% of the company's stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.